GR3019820T3 - Treatment of ocular hypertension with a synergistic combination - Google Patents

Treatment of ocular hypertension with a synergistic combination

Info

Publication number
GR3019820T3
GR3019820T3 GR960401080T GR960401080T GR3019820T3 GR 3019820 T3 GR3019820 T3 GR 3019820T3 GR 960401080 T GR960401080 T GR 960401080T GR 960401080 T GR960401080 T GR 960401080T GR 3019820 T3 GR3019820 T3 GR 3019820T3
Authority
GR
Greece
Prior art keywords
treatment
ocular hypertension
synergistic combination
pharmaceutically acceptable
ketoprostaglandin
Prior art date
Application number
GR960401080T
Other languages
Greek (el)
English (en)
Inventor
Ryuji Ueno
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Publication of GR3019820T3 publication Critical patent/GR3019820T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GR960401080T 1991-03-01 1996-05-02 Treatment of ocular hypertension with a synergistic combination GR3019820T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6132891 1991-03-01

Publications (1)

Publication Number Publication Date
GR3019820T3 true GR3019820T3 (en) 1996-08-31

Family

ID=13167964

Family Applications (1)

Application Number Title Priority Date Filing Date
GR960401080T GR3019820T3 (en) 1991-03-01 1996-05-02 Treatment of ocular hypertension with a synergistic combination

Country Status (11)

Country Link
US (1) US5547968A (enExample)
EP (1) EP0501678B1 (enExample)
JP (1) JP2511611B2 (enExample)
KR (1) KR100221369B1 (enExample)
AT (1) ATE137407T1 (enExample)
CA (1) CA2061907C (enExample)
DE (1) DE69210286T2 (enExample)
DK (1) DK0501678T3 (enExample)
ES (1) ES2089387T3 (enExample)
GR (1) GR3019820T3 (enExample)
TW (1) TW210287B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2270349A1 (en) * 1996-11-01 1998-05-14 Jesse A. May Use of a combination of carbonic anhydrase inhibitors and prostaglandins for treating glaucoma
US6214381B1 (en) 1998-09-08 2001-04-10 Effcon, Inc. Methazolamide composition and method of use
US7128903B2 (en) * 2001-10-03 2006-10-31 Innovative Pharmaceutical Concepts (Ipc) Inc. Pharmaceutical preparations useful for treating tumors and lesions of the skin and the mucous membranes and methods and kits using same
AR043161A1 (es) * 2003-02-14 2005-07-20 Sucampo Pharmaceuticals Inc Composicion oftalmica para tratar hipertension ocular y glaucoma
TWI348386B (en) * 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
KR102074020B1 (ko) * 2012-07-13 2020-02-05 산텐 세이야꾸 가부시키가이샤 술폰아미드 화합물의 조합
US9980946B1 (en) 2017-01-25 2018-05-29 Effcon Laboratories, Inc. Extended release methazolamide formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0242580B1 (en) * 1986-03-13 1993-04-28 The Trustees Of Columbia University In The City Of New York Use of a, b and c prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma
ATE76750T1 (de) * 1987-04-03 1992-06-15 Univ Columbia Anwendung eines prostaglandins in mischung mit einem adrenergischen blocker zur verminderung des augen-innendruckes.
JPH0739343B2 (ja) * 1988-10-01 1995-05-01 株式会社アールテック・ウエノ 眼圧降下剤
GB2209939B (en) * 1987-09-18 1992-01-02 R Tech Ueno Ltd The use of 13,14-dihydro-15-keto-prostaglandins as ocular hypotensive agents
EP0366279B1 (en) * 1988-10-01 1994-09-21 R-Tech Ueno Ltd. Ocular hypotensive agents

Also Published As

Publication number Publication date
JPH0565227A (ja) 1993-03-19
KR920017654A (ko) 1992-10-21
EP0501678A2 (en) 1992-09-02
JP2511611B2 (ja) 1996-07-03
DK0501678T3 (da) 1996-05-28
ES2089387T3 (es) 1996-10-01
KR100221369B1 (ko) 1999-09-15
EP0501678A3 (en) 1992-12-16
ATE137407T1 (de) 1996-05-15
DE69210286D1 (de) 1996-06-05
CA2061907C (en) 2003-04-08
TW210287B (enExample) 1993-08-01
EP0501678B1 (en) 1996-05-01
US5547968A (en) 1996-08-20
CA2061907A1 (en) 1992-09-02
DE69210286T2 (de) 1996-09-12

Similar Documents

Publication Publication Date Title
AU653415B2 (en) Method of treating ocular inflammation
ZA977783B (en) Method of inhibiting fibrosis with a somatostatin agonist
AU7807791A (en) Method of treating impotence
MY133569A (en) Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
PL324330A1 (en) Do- and trivalent low-molecule selectin inhibitors
AU7316591A (en) Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
MY121623A (en) Methods of preventing breast cancer.
EP0501678A3 (en) Treatment of ocular hypertension with a synergistic combination
CA2110410A1 (en) Therapeutic Compositions for Osteoinduction
DK0458588T3 (da) Behandling af okulær hypertension med en synergistisk kombination til okulær administration
CA2190837A1 (en) Transdermal delivery of anti-epileptic drugs
AU7777794A (en) Melatonin derivatives for use in treating sleep disorders
GR3018651T3 (en) Treatment of ocular hypertention with a synergistic combination
AU4228593A (en) Low level laser for soft tissue treatment
CZ223199A3 (cs) Použití inhibitorů COMT nebo jejich farmaceuticky vhodných solí nebo esterů pro výrobu léčiva k prevenci diabetických vaskulárních dysfunkcí
DE69100171D1 (de) Synergistische kombination zur ophthalmischen verwendung.
AU1253288A (en) Composition and method for treatment of peptic ulcers
MY118982A (en) Method of reducing tissue damage associated with ischemia
EP0458537A3 (en) Therapeutic compound for the treatment of bronchitis
GB9526331D0 (en) Novel method
MY104932A (en) Immunomodulatory azaspiranes
NO920719L (no) Injiserbare s-adenosyl-l-metionin-holdige preparater